Mankind Pharma Q2 Profit Rises 38% As Revenue Grows 17%

What happened

Mankind Pharma's consolidated revenue rose 17.3 per cent year on year to Rs 4,338 crore in the second quarter of FY27, ended 30 September 2026, while profit after tax rose 37.7 per cent to Rs 716 crore on strong domestic and export sales.

Confirmed

Global impact / market context

Faster profit growth than revenue growth means the company kept more profit from each sale, helped by EBITDA margin, which means operating profit margin, rising to 27.1 per cent. That supports internal cash generation for future capital spending without relying more on borrowed money.

Analyst inference

Domestic revenue rose 14.8 per cent to Rs 3,657 crore, while exports rose 32.7 per cent to Rs 681 crore, so international markets are a smaller but faster-growing part of the business. Investors may weigh whether export-led growth can offset slower domestic growth.

Analyst inference

What to watch

1. Watch whether domestic revenue growth of 15.9 per cent excluding consumer healthcare and export growth of 32.7 per cent continue, since these segments drove the quarter. Confirmed
2. Watch whether EBITDA margin, which means operating profit margin, holds near 27.1 per cent as sales mix shifts toward exports and chronic therapies. Proposed
3. Watch whether profit growth continues to outpace revenue growth, since that gap reflects cost control and supports cash available for capital spending. Analyst inference

Evidence

• Original source link unavailable